Pins matching tag:Lilly

On 13 May 2022 the US FDA approved Mounjaro (tirzepatide, once weekly), the first dual GIP and GLP-1 receptor agonist, opening Eli Lilly's challenge to Novo Nordisk's semaglutide brands.

On 8 November 2023 the US FDA approved Zepbound (tirzepatide, once weekly) for chronic weight management, with 18% average weight loss at 15 mg over 72 weeks, setting up the Wegovy versus Zepbound rivalry.

Eli Lilly's market value crossed $1 trillion on 21 November 2025, making it the first drugmaker and first health-care company to join the club dominated by tech giants. Its shares hit a record $1,066.65 and closed at $1,059.70, driven by Zepbound and Mounjaro.

Lilly agrees to buy Centessa Pharmaceuticals, maker of the orexin agonist cleminorexton for narcolepsy, for $38 a share in cash (about $6.3 billion) plus a CVR worth up to $1.5 billion more; the deal closed on 24 June 2026.

The FDA approved Eli Lilly's Foundayo, a once-daily GLP-1 pill for weight loss that needs no food or water restrictions, with direct-to-consumer sales from April 6.

People on the top 12 mg dose of Lilly's triple-hormone shot retatrutide lost an average of 28.3% of their body weight (70.3 lbs) over 80 weeks, and 30.3% by two years in the extension - weight loss at the level of bariatric surgery.

Lilly moves into infectious disease by agreeing to buy Curevo (shingles), LimmaTech Biologics (staph and other bacteria) and Vaccine Company (Epstein-Barr virus) for up to $3.83 billion combined in cash.

Lilly agrees to buy Merida Biosciences, whose Phase 1 MER511 is built to destroy the autoantibodies behind Graves' disease and thyroid eye disease, for up to $2.875 billion in cash.

An all-oral pairing that doubled median progression-free survival to 11.1 months from 5.5 in ESR1-mutated patients in the EMBER-3 trial. It is Inluriyo's second FDA approval in under a year.

A 236-acre plant that will make the active ingredient of Lilly's Foundayo weight-loss pill, with more than 600 permanent jobs and about 4,000 construction jobs. Lilly expects it running by 2030.

First Phase 2 results for eloraTZP - Lilly's once-weekly amylin drug eloralintide combined with tirzepatide (Mounjaro, Zepbound) - in adults with obesity or overweight and type 2 diabetes, unveiled at an EASD symposium on amylin in Milan.

Eli Lilly is expected to report third-quarter 2026 results on 29 October, with its usual 10 a.m. ET conference call. It goes in guiding to $85-87 billion of 2026 revenue after second-quarter revenue jumped 48% to $23.0 billion on Mounjaro and Zepbound.

Lilly plans to file its Biologics License Application for retatrutide, the triple-hormone obesity shot that cut weight by up to 28.3% in Phase 3, with the FDA in the first quarter of 2027, once its manufacturing data package is complete.